engage checkpoint medical linkedin twitter

Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Dr. Jaume Capdevila, Dr. Rachel van Leeuwaarde

Podcast with Dr. Jaume Capdevila and Dr. Rachel van Leeuwaarde discussing the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).
Portrait of Jaume Capdevila
Dr. Jaume Capdevila

Medical Oncologist

Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...


Portrait of Rachel van Leeuwaarde
Dr. Rachel van Leeuwaarde


University Medical Centre Utrecht


preview next

time Podcast | open 20 min | Aug 2021

Subscribe to our podcast series on:

I agree that this educational programme:

In this episode, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

This NET CONNECT podcast series is also available on CastosSpotifyApple Podcasts, and Google Podcasts.

NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.

Other programmes of interest

preview next